The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis
- PMID: 31623621
- PMCID: PMC6798752
- DOI: 10.1186/s12917-019-2110-7
The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis
Erratum in
-
Correction to: The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis.BMC Vet Res. 2020 Dec 16;16(1):486. doi: 10.1186/s12917-020-02713-9. BMC Vet Res. 2020. PMID: 33323102 Free PMC article. No abstract available.
Abstract
Background: NSAIDs are accepted as the most predictably efficacious medical treatment of the clinical signs of osteoarthritis (OA). The marine-based fatty-acid compound PCSO-524 has been proposed as an adjunctive treatment for canine OA, however benefits of this agent is still controversial. The purpose of this study was to evaluate and compare the effectiveness of PCSO-524 combined with the NSAID firocoxib using force plate gait analysis, orthopedic assessment score (OAS) and canine brief pain inventory score (CBPI) in dogs with OA. A prospective, randomized, double-blinded study was conducted. Seventy-nine dogs that had hip and/or stifle OA were assigned randomly into three treatment groups: firocoxib, PCSO-524 and combination of firocoxib and PCSO-524, orally for 4 weeks. Peak vertical force (PVF, expressed as a percentage of bodyweight), OAS, CBPI, serum prostaglandin E2 concentration, hematology and blood chemistry values were evaluated before treatment (Day0), as well as at the second (Day14) and fourth week (Day28) during treatment.
Results: Within group analysis revealed significant increases in PVF over the 4-week treatment period for firocoxib, PCSO-524 and the combination (p < 0.05). Mean increases in PVF were 3.25 ± 4.13, 2.01 ± 3.86, 4.11 ± 4.69%BW (mean ± SD) respectively. The OAS showed non-significant change in all treatment groups. There were significant decreases in CBPI pain severity score (PSS) and CBPI pain interference scores (PIS) within some groups over time, however no significant differences were found between the groups. Significantly decreased serum PGE2 concentration (p < 0.05) was found in the combination group. Significant increases in BUN and creatinine (p < 0.05) compared to pre-treatment values were found in the firocoxib and combination groups but not in the PCSO-524 group at day28, but all values in all dogs remained within the normal ranges.
Conclusions: The results of this study suggested combination of both PCSO-524 and firocoxib is more effective in alleviation of inflammation and improvement of weight bearing ability when compared to the uses of either PCSO-524 or firocoxib alone. Further clinical studies are needed to confirm this, and to determine if there is any benefit of PCSO-524 over placebo.
Keywords: Dog; Firocoxib; Gait analysis; NSAIDs; Osteoarthritis; PCSO-524; Treatment.
Conflict of interest statement
BDXL and BB have provided continuing educational lectures sponsored by Pharmalink International. The other authors have no other conflicts of interest to declare.
Similar articles
-
Comparison of force plate gait analysis and owner assessment of pain using the Canine Brief Pain Inventory in dogs with osteoarthritis.J Vet Intern Med. 2013 Jan-Feb;27(1):22-30. doi: 10.1111/jvim.12004. J Vet Intern Med. 2013. PMID: 23311715 Clinical Trial.
-
Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: A prospective, block-randomized, double-blinded, placebo-controlled clinical trial.Front Vet Sci. 2023 Feb 1;10:1033188. doi: 10.3389/fvets.2023.1033188. eCollection 2023. Front Vet Sci. 2023. PMID: 36816197 Free PMC article.
-
Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis.Vet Rec. 2006 Oct 21;159(17):547-51. doi: 10.1136/vr.159.17.547. Vet Rec. 2006. PMID: 17056650 Clinical Trial.
-
Advances in the pharmaceutical treatment options for canine osteoarthritis.J Small Anim Pract. 2022 Oct;63(10):721-738. doi: 10.1111/jsap.13495. Epub 2022 Mar 14. J Small Anim Pract. 2022. PMID: 35285032 Free PMC article. Review.
-
Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis.Vet Clin North Am Small Anim Pract. 1997 Jul;27(4):841-62. doi: 10.1016/s0195-5616(97)50083-0. Vet Clin North Am Small Anim Pract. 1997. PMID: 9243784 Review.
Cited by
-
A blinded, randomized and controlled multicenter field study investigating the safety and efficacy of long-term use of enflicoxib in the treatment of naturally occurring osteoarthritis in client-owned dogs.Front Vet Sci. 2024 Feb 23;11:1349901. doi: 10.3389/fvets.2024.1349901. eCollection 2024. Front Vet Sci. 2024. PMID: 38585299 Free PMC article.
-
Short-term outcomes of cranial cruciate ligament rupture treated surgically with tibial plateau leveling osteotomy or non-surgically in small-breed dogs weighing less than10 kg.J Vet Med Sci. 2024 Apr 10;86(4):428-435. doi: 10.1292/jvms.23-0512. Epub 2024 Feb 29. J Vet Med Sci. 2024. PMID: 38417876 Free PMC article.
-
Therapeutic efficacy and pharmacokinetics of liposomal-cannabidiol injection: a pilot clinical study in dogs with naturally-occurring osteoarthritis.Front Vet Sci. 2023 Aug 23;10:1224452. doi: 10.3389/fvets.2023.1224452. eCollection 2023. Front Vet Sci. 2023. PMID: 37680386 Free PMC article.
-
Preliminary Study on Treatment Outcomes and Prednisolone Tapering after Marine Lipid Extract EAB-277 Supplementation in Dogs with Immune-Mediated Hemolytic Anemia.Vet Sci. 2023 Jun 30;10(7):425. doi: 10.3390/vetsci10070425. Vet Sci. 2023. PMID: 37505830 Free PMC article.
-
An injectable copolymer of fatty acids (ARA 3000 BETA) as a promising treatment for osteoarthritis.Sci Rep. 2023 May 13;13(1):7783. doi: 10.1038/s41598-023-34206-8. Sci Rep. 2023. PMID: 37179423 Free PMC article.